Cargando…
PA01.43. In-vitro cyto chemical & flow-cytometry studies with las02- a coded herbo-mineral compound
PURPOSE: The drug optimization and understanding the mechanisms of action of drugs on the deregulation of cell cycle which is frequently considered as the cause of progression in cancer can provide important insights for new cancer treatment strategies. The drug LAS02 is a herbo mineral drug prepare...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800976/ |
Sumario: | PURPOSE: The drug optimization and understanding the mechanisms of action of drugs on the deregulation of cell cycle which is frequently considered as the cause of progression in cancer can provide important insights for new cancer treatment strategies. The drug LAS02 is a herbo mineral drug prepared as per ancient Ayurvedic literature. METHOD: In this study the effect of LAS02 was studied by analyzing the effect on cell cycle by flow cytometery on cancer cell lines breast cancer (MCF7), cervical cancer (HELA), colon cancer (COLO 205) and prostate cancer (DU 145), procured from NCCS, Pune. The cells were treated by different doses of LAS02, and assay for proliferation was performed by MTT assay test, subsequently, these were analyzed by flow cytometer for cell cycle analysis. RESULT: The results showed inhibition of proliferation in MCF7 by 77% and HELA cells by 78% at dose of 500μg/ml in MTT assay. In cell cycle analysis for COLO 205 treated with LAS02, the percentage retention of the cells in G0/ G1 phase was 73.07% at 300μg/ml as compared to 52.16% in the control after 24hrs. In DU 145, treated with LAS02, cells that retained at G0/G1 phase were 79.28% at a dose of 400μg/ml after 48hrs; as compared to control of 62.41%. The apoptosis observed at 400μg/ml drug concentration was 43.51%. CONCLUSION: The study shows that LAS02 acts as a potent anti cancerous compound by inhibiting proliferation as well as by inducing retention of cells in G0/G1 phase along with apoptosis significantly at in vitro level. Therefore, LAS02 arrests the cancerous cells in G0/G1 phase and prevented the entry of pre cancerous stem cells from G0/G1 phase into G2, the subsequent proliferative stage and inhibits cancer cells from completing the cell cycle. Such a finding is unique with this new drug, which holds a great promise as one of the most effective and safest cancerostatic drug. |
---|